Idiopathic Parkinson's Disease Clinical Trial
Official title:
Facial Expression Recognition of Emotion and Categorization of Emotional Words in Parkinson's Disease. Impact of L-Dopa and Deep Brain Stimulation of Subthalamic Nucleus .
Verified date | January 2011 |
Source | University Hospital, Clermont-Ferrand |
Contact | n/a |
Is FDA regulated | No |
Health authority | France: Ministry of Health |
Study type | Interventional |
Parkinson'disease is a neurodegenerative disorder characterised by bradykinesia, rigidity,
rest tremor and postural instability. Dopaminergic therapy such as L-Dopa and dopamine
agonists usually leads to a dramatic improvement of symptoms, but disease progression
nevertheless remains inevitable. Bilateral Deep brain stimulation in subthalamic nucleus is
now considered the gold standard surgical treatment.
Parkinson'disease mainly affects the nigrostriatal dopaminergic system which is linked to
the limbic system and could be responsible of a specific trouble in the recognition in some
facial expression.
We hypothesise that patients with Parkinson'disease present a dysfunction of voluntary and
automatic treatment of emotional information.
The main purpose of this study is to show if patients with Parkinson'disease present a lack
of specific facial expression recognition of emotion and determinate more precisely if this
alteration involves the cortical way (high frequency way) or the under cortical way (low
frequency way).
We also examine the role of L-Dopa and the deep brain stimulation on emotion perception
Status | Completed |
Enrollment | 80 |
Est. completion date | October 2009 |
Est. primary completion date | October 2008 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 30 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Age : 30-75 years - Patient with an idiopathic Parkinson's disease according to the criteria of the "Parkinson's Disease Society Brain Bank" (Hughes et al., 1992) - Patient treated with a deep brain stimulation according to the French consensus conference of treatment of Parkinson's disease (Consensus Conference Proceeding, 2000) - Effect of the stimulation 50% - Affiliation to social security - Agreement of patients Exclusion Criteria: - Patients suffering of an atypical Parkinson syndrome - Patients with severe tremor before surgery - Patients with a vision contrast altered. - Patients who do not understand the words associated with an emotion - Pregnant women - Person who participate to an other study |
Allocation: Non-Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
France | CHU | Clermont-Ferrand |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Clermont-Ferrand |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Facial expression recognition test | % of exact responses | Yes | |
Secondary | Lexical decision test | The time to respond | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03665493 -
Dopamine Effect on Inhibitory Control
|
N/A | |
Completed |
NCT02227355 -
Evaluating the Effectiveness of Neupro® (Rotigotine) and L-dopa Combination Therapy in Patients With Parkinson's Disease
|
N/A | |
Completed |
NCT01026428 -
A Study to Assess the Effect of Safinamide on Levodopa Pharmacokinetics
|
Phase 1/Phase 2 | |
Completed |
NCT04524143 -
The Acute Effect of Cervical Mobilization in Parkinson's Disease
|
N/A | |
Completed |
NCT05107531 -
Investigation of Gait, Foot Pressure Distribution and Balance in Parkinson's Patients With Motor Freezing
|
||
Completed |
NCT04524182 -
The Acute Effect of Lumbosacral Mobilization in Parkinson's Disease
|
N/A | |
Completed |
NCT00985517 -
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT01968031 -
A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease
|
Phase 3 | |
Completed |
NCT01970813 -
Efficacy of Acupuncture and Bee Venom Acupuncture on Patients With Idiopathic Parkinson's Disease
|
N/A | |
Completed |
NCT01221948 -
Vercise Implantable Stimulator for Treating Parkinson's Disease
|
Phase 2 | |
Terminated |
NCT01028586 -
MOTION, Safinamide in Early Idiopathic Parkinson's Disease (IPD), as add-on to Dopamine Agonist (Extension of Trial 27918)
|
Phase 3 | |
Completed |
NCT00239564 -
Pharmacokinetics and Pharmacodynamics of IPX054 in Subjects With Parkinson's Disease
|
Phase 1/Phase 2 | |
Completed |
NCT02240030 -
Efficacy and Safety Study of CVT-301 In Parkinson's Disease Patients With OFF Episodes
|
Phase 3 | |
Completed |
NCT00605683 -
MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist
|
Phase 3 | |
Completed |
NCT00400634 -
Double-Blind, Multicenter, Sham Surgery Controlled Study of CERE-120 in Subjects With Idiopathic Parkinson's Disease
|
Phase 2 | |
Completed |
NCT01227265 -
Placebo Controlled Study of Preladenant in Participants With Moderate to Severe Parkinson's Disease (P07037)
|
Phase 3 | |
Completed |
NCT02565628 -
PF-06669571 In Subjects With Idiopathic Parkinson's Disease
|
Phase 1 | |
Completed |
NCT01606670 -
Observational Study With Neupro® to Evaluate the Patient´s Perception of Pain Associated With Parkinson´s Disease
|
||
Completed |
NCT01617135 -
Safety, Pharmacokinetics and Efficacy Study of CVT-301 Inpatients With Parkinson's Disease and "Off" Episodes
|
Phase 2 | |
Terminated |
NCT00261781 -
Walking Capacity in Parkinson's Disease (PD-Walk)
|
N/A |